Church & Dwight (CHD) has been experiencing a challenging phase, with its stock underperforming in the market. The Options Market predicts a possible
spike in the stock, while institutions like
State of New Jersey Common Pension Fund D and
AGF Management Ltd. have sold and acquired shares, respectively. Despite recent hurdles, the biotech company's fundamentals appear strong and its
Q2 earnings and revenue exceeded estimates. Nevertheless, Morgan Stanley downgraded the corporation's ratings due to a lack of new catalysts. The company's position gets more complex as
investors turn cautious, leading to a cut in FY forecasts.
Institutional shareholders control a significant 88% of the company. Despite these challenges, Church & Dwight's brand strength remains robust, and it has shown notable sales and
EPS growth in its 2023 results. However,
Morgan Stanley's downgrade raises questions about whether the stock has hit a ceiling. The company undertook various initiatives and made significant announcements, such as the declaration of its
494th regular quarterly dividend and the appointment of a new independent director. Going ahead, the corporation seems uncertain about whether its FY24 guidance can be achieved.
Church Dwight CHD News Analytics from Wed, 31 Aug 2022 07:00:00 GMT to Sun, 15 Sep 2024 14:15:09 GMT -
Rating -3
- Innovation -2
- Information 2
- Rumor 5
